Press Release : Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

 
 
   Heidelberg, Germany, January 15, 2021 -- Affimed N.V. ("Affimed" or the 
"Company") (Nasdaq: AFMD), a clinical stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer, 
today announced the closing of its previously announced public offering 
of 16,666,667 common shares, at the public offering price of $6.00 per 
share, and the exercise in full by the underwriters of their option to 
purchase an additional 2,500,000 common shares. The exercise of the 
option to purchase over-allotment shares brought the total number of 
common shares sold by Affimed to 19,166,667 common shares and increased 
the gross proceeds raised in the offering, before deducting underwriting 
discounts and commissions and estimated expenses of the offering payable 
by Affimed, to $115 million. 
 
   Jefferies LLC, SVB Leerink LLC and Credit Suisse Securities (USA) LLC 
are acting as joint book-running managers and Laidlaw & Company (UK) 
Ltd. is acting as co-manager. A shelf registration statement relating to 
these securities filed with the Securities and Exchange Commission (the 
"SEC") was declared effective by the SEC on December 30, 2020. The 
offering was made only by means of a prospectus and prospectus 
supplement. A prospectus supplement and accompanying prospectus related 
to the offering have been filed with the SEC and are available at the 
SEC's website located at www.sec.gov. Copies of the prospectus 
supplement and accompanying prospectus related to the offering may be 
obtained by contacting Jefferies LLC, Attention: Equity Syndicate 
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 
10022, or by telephone at [phone] or by email at 
[e-mail], SVB Leerink LLC, Attention: 
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, 
by telephone at [phone] ext. 6132, or by email at 
[e-mail], or Credit Suisse Securities (USA) LLC, 
Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, 
NC 27560, by telephone at [phone], or by email at 
[e-mail] 
 
   This press release shall not constitute an offer to sell or a 
solicitation of an offer to buy, nor shall there be any sale of, these 
securities in any state or jurisdiction in which such offer, 
solicitation or sale would be unlawful prior to registration or 
qualification under the securities laws of any such state or 
jurisdiction. 
 
   About Affimed N.V. 
 
   Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company 
committed to giving patients back their innate ability to fight cancer. 
Affimed's fit-for-purpose ROCK(R) platform allows innate cell engagers 
to be designed for specific patient populations. The Company is 
developing single and combination therapies to treat hematologic and 
solid tumors. The Company is currently enrolling patients into a 
registration-directed study of AFM13 for CD30-positive 
relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a 
dose escalation/expansion study of AFM24 for the treatment of advanced 
EGFR-expressing solid tumors. 
 
   Forward-looking Statements 
 
   This press release contains statements that constitute "forward-looking 
statements," including with respect to the proposed offering of common 
shares and the anticipated use of the net proceeds. No assurance can be 
given that the offering discussed above will be completed on the terms 
described, or at all, or that the net proceeds of the offering will be 
used as indicated. Forward-looking statements are subject to numerous 
conditions, many of which are beyond the control of the company, 
including those set forth in the Risk Factors section of the company's 
registration statement and preliminary prospectus for the company's 
offering filed with the Securities and Exchange Commission ("SEC"). 
Copies are available on the SEC's website, www.sec.gov. The company 
undertakes no obligation to update these statements for revisions or 
changes after the date of this release, except as required by law. 
 
   Affimed Investor and Media Contact: 
 
   Alexander Fudukidis, Head of Investor Relations 
 
   E-Mail: [e-mail], [e-mail] 
 
   Tel.: [phone] 
 
 
 
 

(END) Dow Jones Newswires

January 15, 2021 09:21 ET (14:21 GMT)